11月24日，利德曼盘中下跌2.12%，截至13:04，报7.38元/股，成交7349.64万元，换手率1.80%，总市值 40.15亿元。 资金流向方面，主力资金净流出746.68万元，特大单买入106.78万元，占比1.45%，卖出114.30万元，占 比1.56%；大单买入752.37万元，占比10.24%，卖出1491.53万元，占比20.29%。 利德曼今年以来股价涨50.61%，近5个交易日跌20.22%，近20日跌4.28%，近60日跌19.78%。 今年以来利德曼已经4次登上龙虎榜，最近一次登上龙虎榜为8月8日。 分红方面，利德曼A股上市后累计派现1.43亿元。近三年，累计派现544.01万元。 机构持仓方面，截止2025年9月30日，利德曼十大流通股东中，医疗器械ETF（159883）位居第五大流 通股东，持股201.13万股，为新进股东。金元顺安元启灵活配置混合（004685）、华夏中证500指数增 强A（007994）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，北京利德曼生化股份有限公司位于北京市北京经济技术开发区兴海路5号，成立日期1997年 11月5日，上市日期2012年2 ...

Core Viewpoint - The stock of Canar Medical experienced a decline of 3.92% on November 21, with a trading volume of 81.41 million yuan and a total market capitalization of 3.115 billion yuan [1] Group 1: Company Overview - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018 [2] - The company's main business involves the research, production, and sales of injection and puncture instruments as well as laboratory consumables, with key products including puncture needles, syringes, laboratory consumables, and masks [2] - As of November 20, the number of shareholders in Canar Medical was 8,985, an increase of 14.36% from the previous period, while the average circulating shares per person decreased by 12.55% [7] Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Dynamics - The company benefits from a high overseas revenue ratio of 90.61%, which is positively impacted by the depreciation of the yuan [3] - The average trading cost of the stock is 27.89 yuan, with recent rapid outflows of shares suggesting a recommendation for portfolio adjustment [6]

11月21日，西陇科学（维权）盘中上涨2.05%，截至11:01，报8.95元/股，成交2.52亿元，换手率 6.08%，总市值52.38亿元。 资金流向方面，主力资金净流入137.35万元，特大单买入243.27万元，占比0.97%，卖出200.44万元，占 比0.80%；大单买入4279.64万元，占比17.01%，卖出4185.12万元，占比16.63%。 西陇科学今年以来股价涨24.48%，近5个交易日涨3.95%，近20日涨4.19%，近60日跌2.72%。 今年以来西陇科学已经5次登上龙虎榜，最近一次登上龙虎榜为9月24日，当日龙虎榜净买入361.92万 元；买入总计1.20亿元 ，占总成交额比9.07%；卖出总计1.16亿元 ，占总成交额比8.79%。 资料显示，西陇科学股份有限公司位于广东省广州市黄埔区科学城新瑞路6号，成立日期1994年7月19 日，上市日期2011年6月2日，公司主营业务涉及主要从事化学试剂的研发、生产、销售,并从事部分化 工原料、原料药及食品添加剂等业务。主营业务收入构成为：专用化学品62.60%，化工原料15.12%， 电子化学品9.66%，通用试剂7.71%，锂电池正 ...

Core Viewpoint - The stock of Canar Medical experienced a decline of 3.70% on November 20, with a trading volume of 1.11 billion yuan and a market capitalization of 3.242 billion yuan [1] Group 1: Company Overview - Canar Medical began supplying IVF culture tube products to Thermo Fisher in 2018 [2] - The company specializes in the research, production, and sales of injection and puncture instruments, as well as laboratory consumables, with main products including puncture needles, syringes, laboratory consumables, and masks [2] - As of October 31, the number of shareholders in Canar Medical was 7,857, an increase of 4.11% from the previous period, with an average of 9,627 circulating shares per person, a decrease of 3.95% [7] Group 2: Financial Performance - For the period from January to September 2025, Canar Medical reported revenue of 246 million yuan, a year-on-year decrease of 15.86%, and a net profit attributable to shareholders of 8.25 million yuan, down 85.64% year-on-year [7] - The company has distributed a total of 155 million yuan in dividends since its A-share listing, with 122 million yuan distributed over the past three years [8] Group 3: Market Position and Trends - The company benefits from a high overseas revenue ratio, with 90.61% of its revenue coming from international markets, positively impacted by the depreciation of the yuan [3] - The average trading cost of the stock is 27.92 yuan, with recent accumulation activity noted, although the strength of this accumulation is weak [6] - The stock is approaching a resistance level of 27.05 yuan, indicating potential for a pullback unless this level is breached, which could trigger an upward trend [6]

Core Viewpoint - 康德莱's stock price has shown a year-to-date increase of 32.29%, but it has recently experienced a slight decline in the short term [2]. Group 1: Stock Performance - As of November 17, 康德莱's stock price decreased by 2.11% to 9.30 yuan per share, with a trading volume of 21.77 million yuan and a turnover rate of 0.53%, resulting in a total market capitalization of 4.062 billion yuan [1]. - In the past five trading days, 康德莱's stock has dropped by 1.06%, while it has increased by 1.97% over the last 20 days and 4.49% over the last 60 days [2]. Group 2: Financial Performance - For the period from January to September 2025, 康德莱 reported a revenue of 1.721 billion yuan, reflecting a year-on-year growth of 0.95%, and a net profit attributable to shareholders of 194 million yuan, which is a 17.27% increase year-on-year [3]. - Since its A-share listing, 康德莱 has distributed a total of 530 million yuan in dividends, with 231 million yuan distributed over the past three years [4]. Group 3: Shareholder and Institutional Holdings - As of September 30, 2025, 康德莱 had 34,100 shareholders, an increase of 29.67% from the previous period, with an average of 12,826 circulating shares per shareholder, down by 22.88% [3]. - Among the top ten circulating shareholders, 招商成长量化选股股票A and 医疗器械ETF are new entrants, holding 2.4635 million shares and 1.8815 million shares, respectively [4].

Group 1: Strong Stocks - As of November 12, the Shanghai Composite Index fell by 0.07% to 4000.14 points, the Shenzhen Component Index decreased by 0.36% to 13240.62 points, and the ChiNext Index dropped by 0.39% to 3122.03 points [1] - The top three strong stocks today are Moen Electric (002451) with a 7-day continuous rise, Furui Shares (002083) with a 5-day continuous rise, and Dongbai Group (600693) with 4 rises in 6 days [1] - Moen Electric had a turnover rate of 34.88% and a transaction amount of 2.038 billion yuan, while Furui Shares had a turnover rate of 29.45% and a transaction amount of 2.495 billion yuan [1] Group 2: Strong Concept Sectors - The top three concept sectors with the highest increase are Cell Immunotherapy, Combustible Ice, and Monkeypox Concept [2] - The Cell Immunotherapy sector saw a decline of 2.2%, with 71.19% of its component stocks rising [2] - The Monkeypox Concept sector had a decline of 1.57%, with 76.0% of its component stocks increasing [2]

Core Insights - The assisted reproductive concept sector saw a rise of 1.11%, ranking 9th among concept sectors, with 47 stocks increasing in value, including notable gains from companies like Kaineng Health (20% limit up), Zhongsheng Pharmaceutical, and Zhongyuan Harmony, which also hit the limit up [1][2] Group 1: Market Performance - The assisted reproductive sector had a net inflow of 1.149 billion yuan, with 36 stocks receiving net inflows, and 6 stocks exceeding 50 million yuan in net inflow [2] - Zhongsheng Pharmaceutical led the net inflow with 436 million yuan, followed by Zhongyuan Harmony, Hengrui Medicine, and Kaineng Health with net inflows of 220 million yuan, 192 million yuan, and 174 million yuan respectively [2][3] Group 2: Stock Performance - The top performers in the assisted reproductive sector included Kaineng Health (20% limit up), Zhongsheng Pharmaceutical (10.02% increase), and Zhongyuan Harmony (10% increase) [1][3] - The stocks with the largest declines included Haichen Pharmaceutical (-4.96%), Sichuan Shuangma (-3.23%), and Rendu Biotechnology (-2.08%) [1][3] Group 3: Capital Flow Ratios - The highest net inflow ratios were observed in Zhongyuan Harmony (25.74%), Kaineng Health (17.57%), and Zhongsheng Pharmaceutical (14.67%) [3][4]

11月12日，明德生物盘中上涨2.01%，截至13:29，报19.77元/股，成交3910.19万元，换手率1.28%，总 市值45.97亿元。 明德生物所属申万行业为：医药生物-医疗器械-体外诊断。所属概念板块包括：长期破净、破净股、禽 流感药物、辅助生殖、基因测序等。 截至10月31日，明德生物股东户数2.31万，较上期减少2.27%；人均流通股6763股，较上期增加2.32%。 2025年1月-9月，明德生物实现营业收入2.27亿元，同比增长0.53%；归母净利润1351.55万元，同比减少 83.30%。 分红方面，明德生物A股上市后累计派现17.60亿元。近三年，累计派现8.75亿元。 机构持仓方面，截止2025年9月30日，明德生物十大流通股东中，广发价值核心混合A（010377）位居 第四大流通股东，持股284.62万股，持股数量较上期不变。融通中国风1号灵活配置混合A/B（001852） 位居第六大流通股东，持股230.06万股，为新进股东。易方达中证红利ETF（515180）位居第七大流通 股东，持股228.09万股，相比上期增加17.01万股。融通健康产业灵活配置混合A/B（000727） ...

Core Viewpoint - Xinhua Pharmaceutical's stock has shown a modest increase in recent trading sessions, with a year-to-date rise of 5.05%, despite a decline over the past 60 days [1][2]. Group 1: Stock Performance - On November 7, Xinhua Pharmaceutical's stock rose by 2.33%, reaching 16.24 CNY per share, with a trading volume of 1.20 billion CNY and a turnover rate of 1.52% [1]. - The stock has experienced a net inflow of 620.05 thousand CNY from major funds, with significant buying activity from large orders [1]. - Year-to-date, the stock has appeared on the "Dragon and Tiger List" once, with a net purchase of 15.67 million CNY on January 6 [1]. Group 2: Financial Performance - For the period from January to September 2025, Xinhua Pharmaceutical reported a revenue of 6.763 billion CNY, reflecting a year-on-year growth of 0.42%, while the net profit attributable to shareholders decreased by 25.53% to 256 million CNY [2]. - Cumulative cash dividends since the A-share listing amount to 1.17 billion CNY, with 495 million CNY distributed over the past three years [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 7.60% to 70,700, with an average of 0 circulating shares per person [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited and several ETFs, all of which have seen a reduction in their holdings compared to the previous period [3].

11月6日，广生堂盘中上涨2.02%，截至14:23，报108.35元/股，成交6.42亿元，换手率4.41%，总市值 172.57亿元。 资金流向方面，主力资金净流入697.56万元，特大单买入2174.30万元，占比3.39%，卖出2534.36万元， 占比3.95%；大单买入1.52亿元，占比23.63%，卖出1.41亿元，占比21.98%。 广生堂今年以来股价涨231.65%，近5个交易日跌1.40%，近20日涨14.05%，近60日跌6.15%。 资料显示，福建广生堂药业股份有限公司位于福建省福州市闽侯县福州高新区乌龙江中大道7号海西高 新技术产业园创新园二期16号楼，成立日期2001年6月28日，上市日期2015年4月22日，公司主营业务涉 及核苷类抗乙肝病毒药物的研发、生产与销售。主营业务收入构成为：肝胆疾病药物98.54%，其他(补 充)1.46%。 今年以来广生堂已经4次登上龙虎榜，最近一次登上龙虎榜为7月31日。 广生堂所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：熊去氧胆酸、医药电商、 基因测序、辅助生殖、肝炎治疗等。 截至9月30日，广生堂股东户数4.58万，较上期增 ...